Identification of circadian determinants of cancer chronotherapy through In Vitro chronopharmacology and mathematical modeling

Molecular Cancer Therapeutics

Volumn 14, Issue 9, 2015, Pages 2154-2164

  Dulong, Sandrine ^a,b   Ballesta, Annabelle ^c,d   Okyar, Alper ^a,b,e   Levi, Francis ^a,b,c,d,f  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e ISTANBUL UNIVERSITY   (Turkey)

^f HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIRTECAN; IRINOTECAN; MESSENGER RNA; NUCLEAR RECEPTOR NR1D1; PER2 PROTEIN; PROTEIN; SMALL INTERFERING RNA; TOP1 PROTEIN; TRANSCRIPTION FACTOR ARNTL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE;

APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CHRONOTHERAPY; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG ACTIVATION; DRUG DETOXIFICATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG CHRONOTHERAPY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NEOPLASMS; THEORETICAL MODEL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; CIRCADIAN CLOCKS; DNA TOPOISOMERASES, TYPE I; DRUG CHRONOTHERAPY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; MICE; MODELS, THEORETICAL; NEOPLASMS;

EID: 84942162857     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0129     Document Type: Article

References (34)

1. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010;72:517-49.
2. Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 2010;50:377-421.
3. Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 2007;47:593-628.
4. Ortiz-Tudela E, Mteyrek A, Ballesta A, Innominato PF, Levi F. Cancer chronotherapeutics: experimental, theoretical, and clinical aspects. Handb Exp Pharmacol 2013:261-88.
5. Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer 2012;131:2684-92.
6. Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, et al. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer 2013;119:2564-73.
7. Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Levi FA. The circadian timing system in clinical oncology. Ann Med 2014;46:191-207.
8. Mormont MC, Levi F. Circadian-system alterations during cancer processes: a review. Int J Cancer 1997;70:241-7.
9. Ortiz-Tudela E, Iurisci I, Beau J, Karaboue A, Moreau T, Rol MA, et al. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Int J Cancer 2014;134:2717-25.
10. Roche VP, Mohamad-Djafari A, Innominato PF, Karaboue A, Gorbach A, Levi FA. Thoracic surface temperature rhythms as circadian biomarkers for cancer chronotherapy. Chronobiol Int 2014;31:409-20.
11. Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab 2006;4:25-36.
12. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002;109:307-20.
13. Eckel-Mahan KL, Patel VR, Mohney RP, Vignola KS, Baldi P, Sassone-Corsi P. Coordination of the transcriptome and metabolome by the circadian clock. Proc Natl Acad Sci U S A 2012;109:5541-6.
14. Fustin JM, Doi M, Yamada H, Komatsu R, Shimba S, Okamura H. Rhythmic nucleotide synthesis in the liver: temporal segregation of metabolites. Cell Rep 2012;1:341-9.
15. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
16. Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 2012;106:18-24.
17. Ahowesso C. Approche experimentale de la personnalisation de la chronotherapeutique par irinotecan. Universite Paris 2011.
18. Kuramoto Y, Hata K, Koyanagi S, Ohdo S, Shimeno H, Soeda S. Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones. Biochem Pharmacol 2006;71:1155-61.
19. Ahowesso C, Li XM, Zampera S, Peteri-Brunback B, Dulong S, Beau J, et al. Sex and dosing-time dependencies in irinotecan-induced circadian disruption. Chronobiol Int 2011;28:458-70.
20. Ando H, Yanagihara H, Sugimoto K, Hayashi Y, Tsuruoka S, Takamura T, et al. Daily rhythms of P-glycoprotein expression in mice. Chronobiol Int 2005;22:655-65.
21. Okyar A, Piccolo E, Ahowesso C, Filipski E, Hossard V, Guettier C, et al. Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One 2011;6:e20393.
22. Filipski E, Berland E, Ozturk N, Guettier C, van der Horst GT, Levi F, et al. Optimization of irinotecan chronotherapy with P-glycoprotein inhibition. Toxicol Appl Pharmacol 2014;274:471-9.
23. Li XM, Mohammad-Djafari A, Dumitru M, Dulong S, Filipski E, Siffroi-Fernandez S, et al. A circadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res 2013;73:7176-88.
24. Ballesta A, Dulong S, Abbara C, Cohen B, Okyar A, Clairambault J, et al. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput Biol 2011;7:e1002143.
25. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995;55:2116-21.
26. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995;55:2097-103.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
28. Teboul M, Delaunay F. [No hierarchy in mammalian circadian system]. Med Sci (Paris) 2004;20:628-9.
29. Sancar A, Lindsey-Boltz LA, Kang TH, Reardon JT, Lee JH, Ozturk N. Circadian clock control of the cellular response to DNA damage. FEBS Lett 2010;584:2618-25.
30. Mauvoisin D, Wang J, Jouffe C, Martin E, Atger F, Waridel P, et al. Circadian clock-dependent and -independent rhythmic proteomes implement distinct diurnal functions in mouse liver. Proc Natl Acad Sci U S A 2014;111:167-72.
31. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature 2011;473:337-42.
32. Saltelli A, Ratto M, Andres T, Campolongo F, Cariboni J, Gatelli D, et al. Global sensitivity analysis. The primer. Chichester, England: Wiley; 2008.
33. Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, et al. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res 2014;20:1042-52.
34. Miki T, Matsumoto T, Zhao Z, Lee CC. p53 regulates Period2 expression and the circadian clock. Nat Commun 2013;4:2444.